Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

ABSTRACT: This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

DISEASE(S): Carcinoma,Hematologic Neoplasms,Colorectal Cancer,Carcinoma, Adenoid Cystic,Breast Cancer,Non-hodgkin Lymphoma,Neoplasms,Adenoid Cystic Carcinoma,Glomus Tumor, Malignant,Solid Tumour,Haematological Malignancy,Glomus Tumor,Advanced Or Metastatic Solid Tumours And Haematological Malignancies,Osteosarcoma,T-all,Hepatocellular Carcinoma

PROVIDER: 2265066 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Burkholderia pseudomallei CB strain:CB

Project description:Burkholderia pseudomallei CB strain:CB Genome sequencing and assembly

| PRJNA188497 | ENA

Identification of CITED2 target genes in human CB

2014-09-05 | GSE47218 | GEO

Clostridium botulinum strain:CB-27 | isolate:CB-27

Project description:Clostridium botulinum strain:CB-27 | isolate:CB-27 Genome sequencing

| PRJNA611674 | ENA

Identification of CITED2 target genes in human CB

Project description:CB CD34+ cells were were transduced with control (tNGFR) or CITED2 overexpression lentivectors, or control (shSCR) or shRNA CITED2 lentivectors and mRNA was isolated in order to investigate global gene expression changes upon perturbation of CITED2. CB CD34+ cells were isolated by Miltenyi miniMACS column. Cells were prestimulated in HPGM with 100 ng/ml KITL, FLT3L and TPO for 12 hrs. Cells were transduced with control (tNGFR) or CITED2 overexpression lentivectors, or control (shSCR) shRNA CITED2 lentivectors, in three rounds over 48 hrs. Transduced cells were sorted after which RNA was isolated for Illumina beadhchip arrays HT12 v4.

2014-09-05 | E-GEOD-47218 | biostudies-arrayexpress

beta proteobacterium CB

Project description:Beta proteobacterium CB Genome

| PRJNA178293 | ENA

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Project description:This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.

| 2299826 | ecrin-mdr-crc

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Project description:This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

| 2753369 | ecrin-mdr-crc

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Project description:This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.

| 2272421 | ecrin-mdr-crc

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Project description:This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

| 12611 | ecrin-mdr-crc

KZR-261 in Subjects With Advanced Solid Malignancies

Project description:A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprises a Part 1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors (melanoma/uveal melanoma, mesothelioma, colorectal cancer, prostate cancer, and "All-Tumors").

| 2389890 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data